Established by the Hebrew University of Jerusalem and the leading Israeli biotech fund aMoon and Israeli Biotechnology Fund (IBF), the company is developing technology to overcome immuno-oncology resistance (currently 80% of the patients) by leveraging unique insights into the Nectin pathway.